Arbutus Biopharma vs Urogen Pharma
Urogen Pharma is the larger business, with $110m of revenue in fiscal 2025 against $14.1m for Arbutus Biopharma (7.8 times as much). Arbutus Biopharma grew faster (128.2% against 21.4%). Urogen Pharma kept more of each dollar of sales as profit: a net margin of -139.8% against -237.9%.
| Latest fiscal year | Arbutus BiopharmaABUS, 2025 | Urogen PharmaURGN, 2025 |
|---|---|---|
| Revenue | $14.1m | $110m |
| Revenue growth | 128.2% | 21.4% |
| Net income | −$33.5m | −$153m |
| Operating margin | -271.0% | -113.7% |
| Net margin | -237.9% | -139.8% |
| Return on equity | -38.5% | — |
| Free cash flow | −$39.6m | −$163m |
| Cash | $18.0m | $111m |
| Total debt | $0 | $125m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 291 |
| Market value | $771m | $1.68bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 25 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 15 sales |